{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-055442","form_type":"8-K","ticker":"ELVN","cik":"0001672619","company_name":"Enliven Therapeutics, Inc.","filed_at":"2021-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.589740+00:00","generated_at":"2026-06-28T10:47:37.891894+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Imara reports Q3 net loss $13.6M; tovinontrine Phase 2b interim data expected Q4 2021","bullets":["Net loss $13.6M ($0.55/share) vs $12.4M ($0.72/share) in Q3 2020; cash & investments $102.8M.","R&D expenses $10.4M; FY2021 R&D guidance $40-45M, G&A $12-13M; cash runway into Q1 2023.","Phase 2b Ardent (SCD) and Forte (beta-thalassemia) trials fully enrolled; interim data Q4 2021, primary analysis Q1 2022.","New pipeline asset IMR-261 (Nrf2 activator) acquired; preclinical data to be presented at ASH 2021.","Hired cardiologist Dr. Toni Bransford to lead HFpEF Phase 2 trial of tovinontrine; trial expected to start 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-055442","json":"https://secwatch.observer/filing/0001564590-21-055442.json","markdown":"https://secwatch.observer/filing/0001564590-21-055442.md","text":"https://secwatch.observer/filing/0001564590-21-055442.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672619/000156459021055442/0001564590-21-055442-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672619/000156459021055442/imra-8k_20211109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T10:47:37.891894+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}